EUVIMEDEUVIMED entdecken
Crossref

Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones

Tamaki Hoshikawa, Toru Watanabe, Makoto Kotake, Nathalie Tiberghien, Chi-Kit Woo, Sian Lewis, Thomas Briston, Mumta Koglin, James M Staddon, Ben Powney, Anthony H V Schapira, Andrew K Takle

Bioorganic & Medicinal Chemistry Letters · 2023

DOI: 10.1016/j.bmcl.2023.129130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Tamaki Hoshikawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hatfield Research Laboratories, Eisai Ltd., Hatfield AL10 9SN, United Kingdom. Electronic address: t-hoshikawa@hhc.eisai.co.jp. Hauptthemen laut MEDLINE: Parkinson Disease, Gaucher Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 gene, loss of function variants of which cause an autosomal recessive lysosomal storage disorder, Gaucher disease (GD). Heterozygous variants of GBA1 are also known as the strongest common genetic risk factor for Parkinson's disease (PD). Restoration of GCase enzymatic function using a pharmacological chaperone strategy is considered a promising therapeutic approach for PD and GD. We identified compound 4 as a GCase pharmacological chaperone with sub-micromolar activity from a high-throughput screening (HTS) campaign. Compound 4 was further optimised to ER-001230194 (compound 25). ER-001230194 shows improved ADME and physicochemical properties and therefore represents a novel pharmacological chaperone with which to investigate GCase pharmacology further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseGaucher DiseaseHumansGlucosylceramidaseMutationLysosomes

Stichwörter der Autor:innen

Gaucher diseaseGlucocerebrosidaseParkinson’s diseasePharmacological Chaperone

Substanzen

Glucosylceramidase

Autor:innen und Institutionen

  • Hatfield Research Laboratories, Eisai Ltd., Hatfield AL10 9SN, United Kingdom. Electronic address: t-hoshikawa@hhc.eisai.co.jp.
  • Hatfield Research Laboratories, Eisai Ltd., Hatfield AL10 9SN, United Kingdom.
  • Charles River Laboratories, 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

Zitieren

APA

Hoshikawa, T., Watanabe, T., Kotake, M., Tiberghien, N., Woo, C. K., Lewis, S., Briston, T., Koglin, M., Staddon, J. M., Powney, B., Schapira, A. H. V., & Takle, A. K. (2023). Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129130

Vancouver

Hoshikawa T, Watanabe T, Kotake M, Tiberghien N, Woo CK, Lewis S, et al. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129130

BibTeX
@article{Hoshikawa2023,
  author = {Hoshikawa, Tamaki and Watanabe, Toru and Kotake, Makoto and Tiberghien, Nathalie and Woo, Chi-Kit and Lewis, Sian and Briston, Thomas and Koglin, Mumta and Staddon, James M and Powney, Ben and Schapira, Anthony H V and Takle, Andrew K},
  title = {Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  doi = {10.1016/j.bmcl.2023.129130}
}
Kostenlos starten →